BioSpace News Archive

BridGene Biosciences, Inc. today announced that two abstracts featuring the application of the company’s proprietary chemoproteomic platform IMTAC,

Microbot Medical Inc. (Nasdaq: MBOT) announced today, as a continuation of its recent regulatory and future commercialization activities, together with its strategic mission to enable accessibility to multiple endovascular procedures globally, that it has acquired the assets of privately-held Nitiloop Ltd.

ParaPRO today announced that it will unveil Thought Leader AI – a pioneering medical education platform that enables healthcare practitioners to engage “live” with leading clinical experts on topics of public health – at the American Academy of Pediatrics (AAP) National Conference & Exhibition in Anaheim, CA, October 7-11, 2022.

CytoSorbents Corporation announced today that its Chief Financial Officer, Kathleen P. Bloch , MBA, CPA, plans to retire on March 31, 2023 at age 68, following a distinguished decade-long career at the Company.

Bristol Myers Squibb (NYSE:BMY) announced that it has changed the dial-in and replay information of its previously announced third quarter 2022 earnings conference call scheduled for Wednesday, October 26, 2022.

TwinStrand Biosciences, Inc. today announced that the company has implemented a reorganization designed to sustain growth through a focus on key commercial initiatives.

Genprex, Inc. today announced the Company’s participation in the following upcoming investor and industry conferences to be held in October 2022.

Traditional chemotherapies continue to demonstrate limited efficacy in drug-sensitive and drug-resistant solid tumors. InnovoTEX Inc. (InnovoTEX), an Austin -based pharmaceutical company, is developing next generation anti-cancer agents that localize to solid tumors and overcome resistance mechanisms with minimal side effects.

Massive Bio has been named a quarterfinalist in the annual UCSF | Health Hub: Digital Health Awards, which recognize health tech companies that are driving innovation and improving delivery of healthcare.

InVivo Therapeutics Holdings Corp. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company’s common stock.